SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

02 Aug 2023 Evaluate
The Revenue for the quarter ended  June 2023 of Rs. 23002.11 millions grew by 11.59 % from Rs. 20612.51 millions.Good  Net Profit growth of 37.27% reported above the corresponding previous quarter figure of Rs. 2981.64 millions to Rs. 4092.83 millioins.Operating Profit saw a handsome growth to 5969.05 millions from 4391.61 millions in the quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 23002.11 20612.51 11.59 23002.11 20612.51 11.59 81271.53 74862.22 8.56
Other Income 574.36 187.76 205.90 574.36 187.76 205.90 1627.83 2038.14 -20.13
PBIDT 5969.05 4391.61 35.92 5969.05 4391.61 35.92 18601.64 20418.85 -8.90
Interest 19.68 94.29 -79.13 19.68 94.29 -79.13 277.48 471.21 -41.11
PBDT 5949.37 4297.32 38.44 5949.37 4297.32 38.44 18324.16 19947.64 -8.14
Depreciation 685.43 652.21 5.09 685.43 652.21 5.09 2695.80 1233.27 118.59
PBT 5263.94 3645.11 44.41 5263.94 3645.11 44.41 15628.36 18714.37 -16.49
TAX 1171.11 663.47 76.51 1171.11 663.47 76.51 3145.79 4820.13 -34.74
Deferred Tax 78.73 118.93 -33.80 78.73 118.93 -33.80 229.43 529.79 -56.69
PAT 4092.83 2981.64 37.27 4092.83 2981.64 37.27 12482.57 13894.24 -10.16
Equity 400.59 400.59 0.00 400.59 400.59 0.00 400.59 400.59 0.00
PBIDTM(%) 25.95 21.31 21.80 25.95 21.31 21.80 22.89 27.28 -16.08

Mankind Pharma Share Price

2123.20 18.50 (0.88%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×